Vantis Vascular Closes $10 Million Series B-1

<p><span class&equals;"legendSpanClass"><span class&equals;"xn-location"><strong>SAN JOSE<&sol;strong> <&sol;span><&sol;span>&&num;8212&semi; Vantis Vascular&comma; Inc&period;&comma; a pioneering medical technology company founded by physicians with a passion to revolutionize vascular interventions&comma; announced the successful closing of <span class&equals;"xn-money">&dollar;10 million<&sol;span> Series B-1 preferred financing&comma; following a raise of <span class&equals;"xn-money">&dollar;30 million<&sol;span> to date from high-net-worth individuals and National Institute of Health grants&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are proud to have the ongoing support of a strong group of investors who share our vision of transforming how complex interventional procedures are performed&comma;&&num;8221&semi; said <span class&equals;"xn-person">Jason Turner<&sol;span>&comma; Chief Executive Officer at Vantis Vascular&period; &&num;8220&semi;This funding is a critical milestone for Vantis and will allow us to continue our ongoing product development efforts&comma; expand our team and initiate US commercialization of the CrossFAST Advanced Delivery System for complex high-risk PCI procedures&period;&&num;8221&semi;<&sol;p>&NewLine;<p>The CrossFAST System is the first and only dual monorail microcatheter advanced delivery system purpose-built for complex coronary and peripheral interventions&period; Unlike guide extension catheters&comma; which have limited ability to reach targeted areas in high-risk PCIs and demonstrated risk of vessel trauma and damage to previously placed stents&comma; the CrossFAST Advanced Delivery System incorporates an integrated microcatheter with a seamless transition to lower the risk of these adverse events during catheter delivery&period; The CrossFAST System is powered by DuoPRO™ Interlocking Technology&comma; a novel mechanism coupling the microcatheter to the outer delivery catheter&comma; allowing the system to be advanced as one unit for enhanced pushability and efficient navigation&comma; a significant limitation of guide extension catheters&comma; especially in complex high-risk procedures&period;<&sol;p>&NewLine;<p>&&num;8220&semi;With the completion of this financing&comma; we plan to initiate the limited market release of the CrossFAST System in <span class&equals;"xn-location">the United States<&sol;span>&comma;&&num;8221&semi; commented <span class&equals;"xn-person">Gary McCord<&sol;span>&comma; Chief Commercial Officer at Vantis Vascular&period; &&num;8220&semi;We are confident that CrossFAST can safely navigate calcified and tortuous anatomy with ease&comma; empowering physicians to deliver life-saving therapies to patients more effectively than ever before&period;&&num;8221&semi;<&sol;p>&NewLine;<p>The CrossFAST Integrated Microcatheter Advanced Delivery System is commercially available in <span class&equals;"xn-location">the United States<&sol;span> as part of a limited market release&period; Full market release is planned in 2025&period;<&sol;p>&NewLine;